Skip to content
An Initiative of AVAC
Search
Back to Country Data

Country Overview:
Eswatini

Global PrEP Tracker
Last Updated: 5 March 2025

Drug Registration Status

Approved
Not
Approved
Under
Review
Data not
available
Gilead's Truvada (TDF/xTC*) Registration
Approved N/A N/A
Generic versions of TDF/xTC* for prevention
Not Approved
ViiV's Apretude (CAB for PrEP) Registration
Approved 2022 † 2022 †
IPM's Dapivirine Vaginal Ring Registration
Approved 2022 2022
Oral F/TAF (Descovy) Registration
Data Not Available
* TDF/xTC refers to tenofovir disoproxil fumarate (TDF) and either emtricitabine (FTC) or lamivudine (3TC)

Additional Product Approvals Information for Eswatini

† This country uses an alternate pathway for regulatory approval for these products. This country relies on approval from the South African Health Products Regulatory Authority (SAHPRA) and pre-qualification from the World Health Organization (WHO) to authorize an Import License.

Research, Demonstration and Implementation

Oral PrEP

5 Completed Projects

Dapivirine Vaginal Ring

2 Planned/Ongoing Projects

Injectable PrEP

1 Planned/Ongoing Projects

Policy Frameworks

Implementation Plan for the Introduction of the PrEP Ring and Long-acting Injectable Cabotegravir for HIV Prevention – Eswatini, August 2024

Eswatini National Multisectoral HIV/AIDS Strategic Framework, 2018-23

HIV Integrated Management Guidelines, 2022

Est. Cumulative
Initiations:

Total PrEP: 103,845

Oral PrEP: 103,626

Dapivirine Vaginal Ring: 152

Injectable PrEP: 67

Featured Resources

Document

Eswatini Strategic Direction Summary, 2023

Eswatini has made striking progress in controlling the HIV/AIDS epidemic, led by the Government of the Kingdom of Eswatini (GKoE), and in partnership with the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), the Global Fund to Fight AIDS, Tuberculosis and Malaria, other donors, as well as with civil society organizations (CSOs). While Eswatini has…
Document

Private Sector Market Assessment: Eswatini

This market assessment explores the opportunities and barriers to leveraging private sector channels to expand access to new and existing pre-exposure prophylaxis (PrEP) methods, including oral PrEP, the dapivirine vaginal ring (PrEP ring), and long acting cabotegravir (CAB PrEP) in Eswatini.
External Link

Report: Formative research on CAB for PrEP in Eswatini

The goal of this study was to assess access needs, product acceptability, values, and preferences for the new PrEP method. This activity was a collaboration between EpiC and MOSAIC, and included adolescent girls and young women, men who have sex with men, people who inject drugs, female sex workers, pregnant and breastfeeding populations, and transgender…
Document

Eswatini Dapivirine Ring Consultation Analysis

A slide deck considering focused on potential PrEP ring rollout in Eswatini, focused on possible delivery channels and identifying critical steps for introduction.
Document

Digital Health Landscaping Report

This landscape analysis aimed to identify common virtual channels used in several countries, estimate the number of users of each channel, and categorize countries into one of three groups based on potential for interventions to use virtual channels to succeed. Users were defined as adolescent girls and young women (aged 15–24), pregnant or breastfeeding people…
External Link

PrEP-it

Governments, donors, and other stakeholders in countries at the forefront of oral pre-exposure prophylaxis (PrEP) delivery have encountered several programmatic challenges such as difficulty in setting targets, forecasting commodity needs, and estimating program costs and impact. In response, the US President’s Plan for Emergency AIDS Relief (PEPFAR) has developed a web-based tool called PrEP-it for…
View All Resources